Tyruko has been indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active Relapsing-Remitting Multiple Sclerosis (RRMS), a designation also approved by the European Commission for Tysabri, the reference medicine. The introduction of Tyruko is a significant milestone as it is the first and only biosimilar in this space, according to Rebecca Guntern, Sandoz president for Europe.
Guntern emphasized the importance of early treatment with disease-modifying therapies in significantly impacting future disabilities in people living with MS. However, access to high efficacy disease-modifying therapys remains limited, as only about 20% of people living with MS in Europe, and 3% to 4% in Eastern European countries, can leverage these new treatments.
Expanding Access to Vital Biological Medicines: Sandoz’s Commitment to Healthcare Advancement
Sandoz underlines the necessity for early and unrestricted access to these essential medicines to prevent irreversible neurological damage and delay disease progression. In 2019, Sandoz entered a global commercialization agreement with Polpharma Biologics for the biosimilar natalizumab. Polpharma Biologics retains responsibility for the development, manufacturing, and supply of the drug substance under this partnership.
Sandoz holds the right to commercialize and distribute Tyruko in all markets through an exclusive global license, potentially broadening the reach of this important treatment option for RRMS patients. The company provides access to crucial biological medicines across various areas including immunology, oncology, supportive care, endocrinology, and neurology.
Tyruko’s Impact as Disease-Modifying Therapy on RRMS Treatment Access
Sandoz boasts a portfolio with nine marketed biosimilars and another 24 assets in various stages of development. Tyruko’s introduction is expected to improve access to effective and safe therapies for those in Europe who need them most.
The launch of Tyruko in Germany marks a significant step in the treatment of adults with RRMS, offering a potentially effective and safe alternative for patients. It is hoped that this development will lead to a broader reach of this important treatment option and improve access to vital biologic medicines for patients living with RRMS in Europe and potentially worldwide.